SEARCH

SEARCH BY CITATION

References

  • 1
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958965.
  • 2
    Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004; 140; 346355.
  • 3
    Shifffman ML, DiBisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who failed prior treatment. Gastroenterology 2004; 126: 10151023.
  • 4
    Lee SS, Peltekian K, Krajdens M, Yoshida EM, Deschenes M, Heathcote EJ, et al. Treating chronic hepatitis C with pegylated interferon alfa-2a (40kD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006; 23: 397408.
  • 5
    Fried MW, Russo MA. Side effects of antiviral therapy for hepatitis C. Gastroenterology 2003; 124: 17111719.
  • 6
    Fontana RJ. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis 2000; 18; 107116.
  • 7
    Hilsabeck RC, Hassanein TI, Carlson MD, Ziegler EZ, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc 2003; 9: 847854.
  • 8
    Weissenborn K, Krause J, Bokemyer M, Hecker H, Schuler A, Anen JC, et al. Hepatitis C virus infection affects the brain: evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004; 41: 845851.
  • 9
    Fontana RJ, Bieliauskas LA, Back-Madruga C, Lindsay KL, Kronfol Z, Lok ASF, et al. Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J Hepatol 2005; 43: 614622.
  • 10
    Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35: 433439.
  • 11
    McAndrews MP, Farcnik K, Carlen P, Damyanovich A, Mrkonjic M, Jones S, Heathcote EJ. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005; 41: 801808.
  • 12
    Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, et al. Evolution of the HALT-C trial: pegylated interferon as a maintenance therapy for chronic hepatitis C in previous Interferon nonresponders. Control Clin Trials 2004; 25: 472492.
  • 13
    Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 1984; 252; 938941.
  • 14
    Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41: 672676.
  • 15
    Wittchen HU. Reliability and validity studies of the WHO composite international diagnostic interview: a critical review. J Psychiatr Res 1994; 28: 5784.
  • 16
    Skinner HA, Sheu WJ. Reliability of alcohol use indices: the lifetime drinking history and the MAST. J Stud Alcohol 1982; 43: 11571170.
  • 17
    Bieliauskas L, Back-Madruga C, Lindsay KL, Snow KK, Kronfol Z, Lok ASF, et al. Clinical relevance of cognitive scores in patients with advanced fibrosis. J Clin Exp Neuropsychol 2006; 28: 13461361.
  • 18
    McCaffrey RJ, Ortega A, Orsillo SM, Nelles WB, Haase RF. Practice effects in repeated neuropsychological assessments. Clin Neuropsychol 1991; 6: 3242.
  • 19
    Zachary RA. Shipley institute of living scale. Los Angeles: Western Psychological Services, 1991: 135.
  • 20
    Beck AT, Steer RA, Brown GK. BDI-II Manual. The Psychological Corporation. San Antonio, TX: Harcourt Brace and Company, 1996: 120.
  • 21
    Derogatis LR, Melisaratos N. The brief symptom inventory: an introductory report. Psychol Med 1983; 3: 595605.
  • 22
    U.S. Census Bureau, Population Division, Education & Social Stratification Branch. Maintained by: Information & Research Services Internet Staff (Population Division). Created: March 15, 2004.
  • 23
    Pavol MA, Meyers CA, Rexer JL, Valentine AD, Mattis RJ, Talpaz M. Pattern of neurobehavioral deficits associated with interferon-alfa therapy for leukemia. Neurology 1995; 45: 947950.
  • 24
    Merimsky O, Reider-Groswasser I, Inbar M, Chaitchik S. Interferon-related mental deterioration and behavioral changes in patients with renal cell carcinoma. Eur J Cancer 1990; 26: 596600.
  • 25
    Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961966.
  • 26
    Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1991; 41: 672676.
  • 27
    Juengling FD, Ebert D, Gut O, Engelbrecht MA, Rasenack J, Nitzsche EU, et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl) 2000; 152: 383389.
  • 28
    Hollander A, Foster GR, Weiland O. Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scand J Gastroenterol 2006; 41: 577585.
  • 29
    Caraceni A, Gangeri L, Martini C, Belli F, Brunelli C, Baldini M, et al. Neurotoxicity of interferon-a in melanoma therapy: results from a randomized controlled trial. Cancer 1998; 83; 482489.
  • 30
    Mapou RL, Law WA, Wagner K, Malone JL, Skillman DK. Neuropsychological effects of interferon alfa-n3 treatment in asymptomatic human immunodeficiency virus-1-infected individuals. J Neuropsychiatry Clin Neurosci 1996; 8: 7481.
  • 31
    Amodio P, De Toni EN, Cavalletto L, Mapelli D, Bernardinello E. Del Piccolo F, et al. Mood, cognition and EEG changes during interferon α (alfa-IFN) treatment for chronic hepatitis C. J Affect Disord 2005; 84: 9398.
  • 32
    Hilsabeck RC, Hassanein TI, Ziegler EA, Carlson MD, Perry W. Effect of interferon a on cognitive functioning in patients with chronic hepatitis C. J Int Neuropsychol Soc 2005; 11: 1622.
  • 33
    Collie A, Maruff P, Darby DG, McStephen M. The effects of practice on the cognitive test performance of neurologically normal individuals assessed at brief test-retest intervals. J Int Neuropsychol Soc 2003; 9: 419428.
  • 34
    Lemay S, Bedard M, Roleau I, Tremblay P. Practice effect and test-retest reliability of attentional and executive tests in middle-aged to elderly subjects. Clin Neuropsychol 2004; 18: 284302.
  • 35
    McCaffrey RJ, Ortega A, Orsillo SM, Neiles WB, Haase RF. Practice effects in repeated neuropsychological assessment. Clin Neuropsychol 1992; 6: 3242.
  • 36
    Hannay HJ, Levin HS. Selective reminding test: an examination of the equivalence of four forms. J Clin Exp Neuropsychol 1985; 7: 251263.
  • 37
    Basso MR, Bornstein RA, Lang JM. Practice effects of commonly used measures of executive function across twelve months. Clin Neuropsychol 1999; 13: 283292.
  • 38
    Beglinger LJ, Crawford-Miller, Kareken DA. Neuropsychological practice effects and change detection in people with schizophrenia. Schizophr Res 2003; 62: 191194.
  • 39
    Paradee CV, Rapport LJ, Hanks RA, Levy JA. Circadian preference and cognitive functioning among rehabilitation inpatients. Clin Neuropsychol 2005; 19: 5572.
  • 40
    Dan AA, Martin LM, Crone C, Ong JP, Farmer DW, Wise T, et al. Depression, anemia, and health-related quality of life in chronic hepatitis C. J Hepatol 2006; 44: 491498.
  • 41
    Benedict RHB, Cox D, Thompson LL, Foley F, Weinstock-Guttman B, Munschauer F. Reliable screening for neuropsychological impairment in multiple sclerosis. Mult Scler 2004; 10: 675678.
  • 42
    Randolph JJ, Arnett PA, Freske P. Metamemory in multiple sclerosis: Exploring affective and executive contributors. Arch Clin Neuropsychol 2004; 19: 259279.
  • 43
    Elixhauser A, Leidy NK, Meador K, Means E, Willan MK. The relationship between memory performance, perceived cognitive function and mood in patients with epilepsy. Epilepsy Res 1999; 37: 1324.
  • 44
    Banos JH, LaGory J, Sawrie S, Faught E, Knowlton R, Prasad A, et al. Self-report of cognitive abilities in temporal lobe epilepsy:cognitive, psychosocial, and emotional factors. Epilepsy Behav 2004; 5: 575579.
  • 45
    Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001; 358: 3839.
  • 46
    Radkowski M, Wilkinson J, Nowicki M, Adair D, Vargas H, Knguid C, et al. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 2002; 76: 600608.
  • 47
    Mayr N, Zeithofer J, Deecke L, Fritz E, Ludwig H, Gisslinger H. Neurological function during long-term therapy with recombinant interferon-alpha. J Neuropsychiatry Clin Neurosci 1999; 11: 343348.
  • 48
    Barak Y, Achiron A. Effect of interferon-beta-1b on cognitive function in multiple sclerosis. Eur Neurol 2002; 47: 1114.
  • 49
    Weissenborn K, Ennen JC, Bokemeyer M, Ahl B, Wurster U, Tillmann HL, et al. Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut 2006; 55: 16241630.
  • 50
    Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpe S, Maes M. IDO and interferon-a induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 2005; 10: 538544.